China’s Insatiable Appetite For Latest Therapies Prompts Ex-Exec To Take New Journey
Neukio Sees NK Promise
After immuno-oncology, cell therapies such as CAR-Ts have attracted millions of dollars of funding in China and one former executive is now sailing into the largely uncharted waters of natural killer cells.
You may also be interested in...
Gracell and FutureGen and NovaRock and Flame partner in Claudin 18.2 antibody R&D for cancer. Plus deals involving HDT Bio/Quratis, Pfizer China/Ferring and Antengene/MindRank AI.
Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.
In a vote of confidence, investors predict Shanghai IPOs to rise in 2022, while sluggish share performances in Hong Kong have made a public listing there more “a liquidity rather than an exit event.”